These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7199474)

  • 1. Inability of liposome encapsulated 1-beta-D-arabinofuranosylcytosine nucleotides to overcome drug resistance in L1210 cells.
    Rustum YM; Mayhew E; Szoka F; Campbell J
    Eur J Cancer Clin Oncol; 1981 Jul; 17(7):809-17. PubMed ID: 7199474
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosylcytosine (ara-C).
    Riva CM; Rustum YM; Preisler HD
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):1-8. PubMed ID: 3859925
    [No Abstract]   [Full Text] [Related]  

  • 3. Enhancement of 1-beta-D-arabinofuranosylcytosine accumulation within L1210 cells and increased cytotoxicity following thymidine exposure.
    Grant S; Lehman C; Cadman E
    Cancer Res; 1980 May; 40(5):1525-31. PubMed ID: 7370990
    [No Abstract]   [Full Text] [Related]  

  • 4. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response.
    Riva CM; Rustum YM
    Cancer Res; 1985 Dec; 45(12 Pt 1):6244-9. PubMed ID: 2998596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of the 5'-triphosphates of arabinosylcytosine and 2',2'-difluorodeoxycytidine in L1210 cells.
    Plunkett W; Grindey GB
    Nucleic Acids Symp Ser; 1987; (18):77-9. PubMed ID: 3697155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methotrexate-induced changes in the levels of 1-beta-D-arabinofuranosylcytosine triphosphate in L1210 cells.
    Roberts D; Peck C; Hilliard S; Wingo W
    Cancer Res; 1979 Oct; 39(10):4048-54. PubMed ID: 476642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dephosphorylation of nucleotides of 1-beta-D-arabinofuranosylcytosine in relation to the different drug sensitivity in tumor cells.
    Abe I; Sato H
    Tohoku J Exp Med; 1979 Mar; 127(3):281-8. PubMed ID: 442078
    [No Abstract]   [Full Text] [Related]  

  • 8. Biochemical and antitumor effects of the combination of thymidine and 1-beta-D-arabinofuranosylcytosine against leukemia L1210.
    Kinahan JJ; Kowal EP; Grindey GB
    Cancer Res; 1981 Feb; 41(2):445-51. PubMed ID: 7448789
    [No Abstract]   [Full Text] [Related]  

  • 9. Cellular pharmacology and optimal therapeutic concentrations of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-beta-D-arabinofuranosylcytosine.
    Plunkett W; Iacoboni S; Keating MJ
    Scand J Haematol Suppl; 1986; 44():51-9. PubMed ID: 3457439
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect and mode of action of N4-behenoyl-beta-D-arabinofuranosylcytosine.
    Kataoka T; Sakurai Y
    Recent Results Cancer Res; 1980; 70():147-51. PubMed ID: 7355245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1-beta-D-arabinofuranosylcytosine conjugates of thioether phospholipids as a new class of potential antitumor drugs.
    Hong CI; Kirisits AJ; Buchheit DJ; Nechaev A; West CR
    Cancer Drug Deliv; 1986; 3(2):101-13. PubMed ID: 3708534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic cells after intravenous and subcutaneous administration of 1-beta-D-arabinofuranosylcytosine.
    Liliemark JO; Paul CY; Gahrton CG; Peterson CO
    Cancer Res; 1985 May; 45(5):2373-5. PubMed ID: 3986778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ara-CTP metabolism following hydroxyurea or methotrexate treatment in human leukemia cell lines.
    Kubota M; Takimoto T; Kitoh T; Tanizawa A; Akiyama Y; Kiriyama Y; Mikawa H
    Adv Exp Med Biol; 1989; 253B():363-7. PubMed ID: 2610124
    [No Abstract]   [Full Text] [Related]  

  • 14. Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and response to therapy.
    Rustum YM; Preisler HD
    Cancer Res; 1979 Jan; 39(1):42-9. PubMed ID: 282940
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of liposomes for the enhancement of the cytotoxic effects of cytosine arabinoside.
    Mayhew E; Papahadjopoulos D; Rustum YM; Dave C
    Ann N Y Acad Sci; 1978; 308():371-86. PubMed ID: 279297
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity.
    Abe I; Saito S; Hori K; Suzuki M; Sato H
    Cancer Res; 1982 Jul; 42(7):2846-51. PubMed ID: 7083175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of liposome type and route of administration in the antitumor activity of liposome-entrapped 1-beta-D-arabinofuranosylcytosine against mouse L1210 leukemia.
    Rustum YM; Dave C; Mayhew E; Papahadjopoulos D
    Cancer Res; 1979 Apr; 39(4):1390-5. PubMed ID: 421223
    [No Abstract]   [Full Text] [Related]  

  • 18. Prediction of sensitivity to 1-beta-D-arabinofuranosylcytosine by the plateau level of its 5'-triphosphate in human lymphoblastic cell lines in vitro.
    Abe I; Saito S; Hori K; Suzuki M; Sato H
    Eur J Cancer Clin Oncol; 1983 Jul; 19(7):941-4. PubMed ID: 6576907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-beta-D-arabinofuranosylcytosine nucleotide inhibition of sialic acid metabolism in WI-38 cells.
    Myers-Robfogel MW; Spataro AC
    Cancer Res; 1980 Jun; 40(6):1940-3. PubMed ID: 7371029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of chemotherapeutic effect by entrapping 1-beta-D-arabinofuranosylcytosine in lipid vesicles and its mode of action.
    Kataoka T; Kobayashi T
    Ann N Y Acad Sci; 1978; 308():387-94. PubMed ID: 279298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.